Please ensure Javascript is enabled for purposes of website accessibility

Why Intersect ENT Is Down Big Today

By Brian Feroldi – Aug 2, 2019 at 2:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares dropped after the company reported second-quarter results that missed the mark, and cut guidance.

What happened

Shares of Intersect ENT (XENT), a medical device company focused on products that treat ear, nose, and throat problems, are down 17% as of 2:10 p.m. EDT on Friday. The huge drop is attributable to disappointing quarterly results.

So what

Here are Intersect ENT's headline numbers from the quarter:

  • Revenue rose 1% to $26.7 million. That was slightly behind Wall Street's estimate.
  • Gross margin improved by 200 basis points to 81%.
  • Operating expenses jumped 33% to $33.7 million.
  • Net loss more than doubled to $11.4 million, or $0.36 per share. That was worse than the $0.34-per-share loss analysts were expecting.
  • Cash balance at quarter-end was $93.5 million.

The worse-than-expected quarterly results were bad enough, but management poured salt on the wound by cutting guidance, too:

  • Full-year revenue is now expected to be about flat, at $108.5 million. That's down from Intersect's prior range of $113 million to $117 million.
  • 2019 operating expenses are still expected to land between $135 million and $137 million.
Businessman at laptop giving the thumbs-down sign

Image source: Getty Images.

Given the poor results and guidance cut, it's no surprise to see shares getting whacked again.

Now what

Intersect ENT recently hired Tom West as its new CEO. West has been in the medical device industry for a long time and has held executive roles at Hologic and at Johnson & Johnson, so he seems to be a good fit to turn this business around.

If West can return Intersect ENT to growth, then shares could be viewed as a bargain today. However, that's easier said than done. That's why my plan remains to root for Intersect's success from the safety of the sidelines, and to be willing to jump in only after we see clear signs that the recovery is taking hold.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intersect ENT, Inc. Stock Quote
Intersect ENT, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.